MERCK HIV PROTEASE INHIBITOR TRIALS: HIGHER DOSE WILL BE TESTED
MERCK HIV PROTEASE INHIBITOR TRIALS: HIGHER DOSE WILL BE TESTED in light of potential resistance that has emerged to L- 735,524 in early clinical trials, Merck said. Initial trials evaluated 400 mg four times daily. With the apparent emergence of resistance, Merck is proposing to increase the dose in the 60 patient Phase II study to 600 mg q.i.d.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth